|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Denosumab治疗绝经后妇女低骨密度显示文摘Background: Receptor activator of nuclear factor- κ B ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162)- binds RANKL with high affinity and specificity and inhibits RANKL action. Methods: The efficacy and safety of subcutaneously administered denosumab were evaluated over a period of 12 months in 412 postmenopausal women with low bone mineral density (T score of- 1.8 to - 4.0 at the lumbar spine or- 1.8 to- 3.5 at the proximal femur). Subjects were randomly assigned to receive denosumab either every three months (at a dose of 6, 14, or 30 mg) or every six months (at a dose of 14, 60, 100, or 210 mg), open- label oral alendronate once weekly (at a dose of 70 mg), or placebo. The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Changes in bone turnover were assessed by measurement of serum and urine telopeptides and bone-specific alkaline phosphatase. Results: Denosumab treatment for 12 months resulted in an increase in bone mineral density at the lumbar spine of 3.0 to 6.7 percent (as compared with an increase of 4.6 percent with alendronate and a loss of 0.8 percent with placebo), at the total hip of 1.9 to 3.6 percent (as compared with an increase of 2.1 percent with alendronate and a loss of 0.6 percent with placebo), and at the distal third of the radius of 0.4 to 1.3 percent (as compared with decreases of 0.5 percent with alendronate and 2.0 percent with placebo). Near-maximal reductions in mean levels of serum C- telopeptide from baseline were evident three days after the administration of denosumab. The duration of the suppression of bone turnover appeared to be dose-dependent. Conclusions: In postmenopausal women with low bone mass, denosumab increased bone mineral density and decreased bone resorption. These preliminary data suggest that denosumab might be an effective treatment for osteoporosis. | Mc Clung M.R. Michael Lewiecki E. Cohen S.B. 马超 | 2006 | 世界核心医学期刊文摘(妇产科学分册)2006，0，8： | 19 |
| 2 | Sclerostin: a novel target for intervention in the treatment of osteoporosis显示文摘 | Lewiecki EM | 2011 | Discovery Medicine2011，12，65： | 1 |
| 3 | New targets for intervention in the treatment of post-menopausal osteoporosis 显示文摘 | Lewiecki EM | 2011 | Nat Rev Rheumatol2011，7，11： | 1 |
| 4 | Clinical use of serum and urine bone markers in the management of osteoporosis显示文摘 | SRIVASTAVA A K VLIET E L LEWIECKI E M | 2005 | Curr Med Res Opin2005，21，： | 1 |
| 5 | Clinical use of serum and urine bone markers in the management of osteoporosis显示文摘 | Srivastava AK Vliet EL Lewiecki EM | 2005 | Curr Med Res Opin2005，21，7： | 1 |
| 6 | Clinical applications of bone density testing for osteo- porosis 显示文摘 | Lewiecki EM | 2005 | Minerva Med2005，96，： | 1 |
| 7 | Skeletal effects of primary hyperpara-thyroidism:bone mineral density and fracture risk 显示文摘 | Lewiecki EM Miller PD | 2013 | J ClinDensitom2013，16，1： | 1 |
| 8 | Emerging drugs for postmenopausal osteoporosis显示文摘 | Lewiecki E M | 2009 | Expert Opin Emerging Drugs2009，14，1： | 1 |
| 9 | Preci- sion assessment and radiation safety for dual-energy X-ray absorptiometry : Position paper of the International Society for Clinical Densitometry 显示文摘 | BAIM S WILSON C R LEWIECKI E M | 2008 | Journal of Clinical Densi- tometry2008，8，4： | 1 |
| 10 | Sclerostin: a novel target for intervention in the treatment of osteoporosis显示文摘 | Lewiecki EM | 2011 | Discov Med2011，12，： | 1 |
| 11 | National Osteoporosis Foundation Clinician' s Guide to Prevention and Treatment of Osteoporosis 2008显示文摘 | Watts NB Lewiecki EM Miller PD | 2008 | J Clin Densitom2008，11，4： | 1 |
| 12 | Sclerostin inhibition:a novel therapeutic approach in the treatment of osteoporosis显示文摘 | SHAH A D SHOBACK D LEWIECKI E M | 2015 | International Journal of Women′s Health2015，7，： | 1 |
| 13 | The pathophysiology and treatment of osteoporosis显示文摘 | Drake MT Clarke BL Lewiecki EM | 2015 | Clin Ther2015，37，： | 1 |
| 14 | National Os tcoporosis Foundation Clinician's Guide to Prevention and Treat ment of Osteoporosis 2008 显示文摘 | WATTS NB LEWIECKI EM MILLER PD | 2008 | J Clin Densitom2008，11，4： | 1 |
| 15 | Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases显示文摘 | LEWIECKI E M | 2014 | Therapeutic Advances in Musculoskeletal Disease2014，6，2： | 1 |
| 16 | Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD显示文摘 | Lewiecki EM Miller PD McClung MR | 2007 | J Bone Miner Res2007，22，12： | 1 |
| 17 | Intravenous zoledronic acid for thetreatment of osteoporosis:The evidence of its therapeuticeffect显示文摘 | LEWIECKI E M | 2010 | Core Evid2010，15，4： | 1 |
| 18 | Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis显示文摘 | Lewiecki EM | 2009 | J Women''s Health2009，18，10： | 1 |
| 19 | Phytoestrogens and Their Role in the Management of Postmenopausal Osteoporosis显示文摘 | E Michael Lewiecki | 2009 | Southern Medical Journal2009，，1： | 1 |
| 20 | Update on osteoporosis from the 2014 Santa Fe Bone symposium 显示文摘 | Lewiecki EM Bilezikian JP Binkley N | 2015 | Endocrine Research2015，25，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员